


Supplementary Online Content

Greene DN, Schmidt RL, Christenson RH, et al. Distribution of high-sensitivity cardiac troponin and N-terminal pro–brain natriuretic peptide in healthy transgender people. *JAMA Cardiol.* Published online October 5, 2022. doi:10.1001/jamacardio.2022.3299

eFigure. Distribution of hs-cTnI in Transgender Men and Women Using the Beckman ACCESS hs-cTnI and Roche TnT Gen 5 STAT Assay

This supplementary material has been provided by the authors to give readers additional information about their work.

eFigure. Distribution of hs-cTnI in Transgender Men and Women Using the Beckman ACCESS hs-cTnI and Roche TnT Gen 5 STAT Assay



Abbreviations: TM, transgender men; TW, transgender women.

For Beckman hs-cTnI the median concentration observed in transgender men and women was 1.4 ng/L (IQR=1.0-2.1 ng/L) and 1.1 ng/L (IQR=0.9-1.5 ng/L), respectively (p=0.005). For Roche hs-cTnT the median concentration observed in transgender men and women was 4.6 ng/mL (IQR=4.0-5.2 ng/L) and 4.1 ng/L (IQR=3.5-4.8 ng/L), respectively (p=0.002). The limit of the blank, limit of detection and limit of quantitation, respectively, for each assay are 0.072 ng/L, 0.32 ng/L, and 0.77 ng/L for the Beckman assay; and 2.5 ng/L, 3.0 ng/L, and 6.0 ng/L for the Roche assay. The 99th URLs for the overall, female and male healthy populations, respectively, are 18.2 ng/L, 11.6 ng/L and 18.2 ng/L for the Beckman assay; and 19 ng/L, 14 ng/L and 22 ng/L for the Roche assay.